Advertisement
Singapore markets closed
  • Straits Times Index

    3,300.04
    -3.15 (-0.10%)
     
  • S&P 500

    5,187.91
    +7.17 (+0.14%)
     
  • Dow

    38,969.85
    +117.58 (+0.30%)
     
  • Nasdaq

    16,331.40
    -17.84 (-0.11%)
     
  • Bitcoin USD

    63,302.43
    -780.96 (-1.22%)
     
  • CMC Crypto 200

    1,313.07
    -52.05 (-3.81%)
     
  • FTSE 100

    8,314.04
    +100.55 (+1.22%)
     
  • Gold

    2,329.80
    -1.40 (-0.06%)
     
  • Crude Oil

    77.89
    -0.59 (-0.75%)
     
  • 10-Yr Bond

    4.4390
    -0.0500 (-1.11%)
     
  • Nikkei

    38,835.10
    +599.03 (+1.57%)
     
  • Hang Seng

    18,479.37
    -98.93 (-0.53%)
     
  • FTSE Bursa Malaysia

    1,605.68
    +8.29 (+0.52%)
     
  • Jakarta Composite Index

    7,123.61
    -12.28 (-0.17%)
     
  • PSE Index

    6,618.58
    -33.91 (-0.51%)
     

Understanding Nektar Therapeutics’ Top-Line Performance

Understanding Nektar Therapeutics’ Top-Line Performance

Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) generates revenues from collaboration agreements through which it receives product sales revenues, royalties, license fees, milestone payments, and contract research payments. In fiscal 2017, Nektar Therapeutics generated total revenues of $307.7 million compared with $165.4 million in fiscal 2016.